Jan, 2025

U.S.A.
News / Corporate
U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) accepted the revised supplemental New Drug Application...
Read More
U.S.A.
News / Corporate
China's National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- China has the highest number of cases and deaths from gastric cancer of any country worldwide1 - - Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a...
Read More

Nov, 2024

U.S.A.
News / Corporate
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DOHC), a member of Heritage Provider...
Read More

Sep, 2024

U.S.A.
News / Corporate
Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing...
Read More
U.S.A.
News / Corporate
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
- New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring - TOKYO, Sept. 18, 2024 /PRNewswire/ --...
Read More